Mineralys Therapeutics, Inc. MLYS Payments to Acquire Held-to-Maturity Securities
Payments to Acquire Held-to-Maturity Securities at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s payments to acquire held-to-maturity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s payments to acquire held-to-maturity securities?
- Mineralys Therapeutics, Inc. (MLYS) reported payments to acquire held-to-maturity securities of $347.44M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s payments to acquire held-to-maturity securities changed year-over-year?
- Mineralys Therapeutics, Inc.'s payments to acquire held-to-maturity securities increased by 171.7% year-over-year, from $127.88M to $347.44M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s payments to acquire held-to-maturity securities?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s payments to acquire held-to-maturity securities has grown at a 124.8% compound annual growth rate (CAGR), from $71.76M to $814.74M.